Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Follow-Up Questions
Altimmune Inc의 CEO는 누구입니까?
Dr. Vipin Garg은 2018부터 회사에 합류한 Altimmune Inc의 President입니다.
ALT 주식의 가격 성능은 어떻습니까?
ALT의 현재 가격은 $3.89이며, 전 거래일에 increased 1.59% 하였습니다.
Altimmune Inc의 주요 사업 주제나 업종은 무엇입니까?
Altimmune Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Altimmune Inc의 시가총액은 얼마입니까?
Altimmune Inc의 현재 시가총액은 $343.4M입니다
Altimmune Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 10명의 분석가가 Altimmune Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 8명의 매수, 2명의 보유, 1명의 매도, 그리고 3명의 강력한 매도를 포함합니다
